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A B S T R A C T
Background
The von Hippel–Lindau tumour suppressor protein–hypoxia-inducible factor (VHL–HIF)
pathway has attracted widespread medical interest as a transcriptional system controlling
cellular responses to hypoxia, yet insights into its role in systemic human physiology remain
limited. Chuvash polycythaemia has recently been defined as a new form of VHL-associated
disease, distinct from the classical VHL-associated inherited cancer syndrome, in which
germline homozygosity for a hypomorphic VHL allele causes a generalised abnormality in VHL–
HIF signalling. Affected individuals thus provide a unique opportunity to explore the integrative
physiology of this signalling pathway. This study investigated patients with Chuvash
polycythaemia in order to analyse the role of the VHL–HIF pathway in systemic human
cardiopulmonary physiology.
Methods and Findings
Twelve participants, three with Chuvash polycythaemia and nine controls, were studied at
baseline and during hypoxia. Participants breathed through a mouthpiece, and pulmonary
ventilation was measured while pulmonary vascular tone was assessed echocardiographically.
Individuals with Chuvash polycythaemia were found to have striking abnormalities in
respiratory and pulmonary vascular regulation. Basal ventilation and pulmonary vascular tone
were elevated, and ventilatory, pulmonary vasoconstrictive, and heart rate responses to acute
hypoxia were greatly increased.
Conclusions
The features observed in this small group of patients with Chuvash polycythaemia are highly
characteristic of those associated with acclimatisation to the hypoxia of high altitude. More
generally, the phenotype associated with Chuvash polycythaemia demonstrates that VHL plays
a major role in the underlying calibration and homeostasis of the respiratory and cardiovascular
systems, most likely through its central role in the regulation of HIF.
The Editors’ Summary of this article follows the references.
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Introduction
Hypoxia is universally experienced at high altitudes and is
a detrimental feature of many medical conditions. The
human response to acute hypoxia includes hyperventilation,
pulmonary vasoconstriction, systemic peripheral vasodila-
tion, and tachycardia. Our understanding of how these
systemic responses are evoked and regulated remains limited.
However, it is now known that intracellular responses to
hypoxia are coordinated by the hypoxia-inducible factor
(HIF) family of transcription factors, which directly or
indirectly regulate the expression of several hundred genes
in any given cell type [1]. The von Hippel–Lindau tumour
suppressor protein (VHL) is an essential component in the
degradation pathway through which HIF is primarily regu-
lated [2,3]. The HIF-a subunit is synthesised continuously but
is rapidly destroyed in the presence of oxygen. Oxygen-
dependent prolyl hydroxylases hydroxylate speciﬁc residues
in HIF-a, increasing its afﬁnity for VHL [4,5]. The binding of
VHL to hydroxylated HIF-a then targets HIF-a for destruc-
tion by the ubiquitin–proteasome pathway [2,3]. Under
hypoxic conditions, the hydroxylation of HIF-a is inhibited,
proteasomal degradation is slowed, and thus there is rapid
accumulation of HIF with subsequent up-regulation of
hypoxia-responsive genes. Manipulation of the VHL–HIF
pathway is currently under intense investigation as a treat-
ment for cancer and ischaemic/hypoxic vascular disease [6].
However, the role of the VHL–HIF pathway in systems-level
human physiology remains largely unknown.
In the classical VHL-associated inherited cancer syndrome,
affected individuals are heterozygous for a germline VHL
mutation that predisposes to speciﬁc types of tumour [7].
Known clinical manifestations are conﬁned to tumours and
discrete benign lesions that arise following somatic inactiva-
tion of the second allele. Disturbance of hypoxia signalling is
limited to tumour cells, and studies of these effects have been
conﬁned to the phenotype of associated renal cell carcinoma
and to lesions that develop in rodent models of VHL
inactivation. Such analyses essentially examine the effects of
complete dysregulation of the VHL–HIF system at the
cellular level.
Chuvash polycythaemia (CP) is a rare autosomal recessive
disorder caused by an entirely distinct disease mechanism.
Affected individuals are homozygous for a speciﬁc 598C.T
mutation in VHL [8] that impairs but does not ablate the
regulation of HIF—potentially allowing insights into its
systemic functions in humans. The VHL mutation diminishes
VHL’s binding afﬁnity for hydroxylated HIF-a, thereby
partially inhibiting HIF-a degradation and pathologically up-
regulating HIF target genes including erythropoietin (EPO) [8].
CP is characterised by congenital erythrocytosis, but has yet to
be extensively phenotyped. Through experiments conducted
with CP patients, this study aimed to investigate the potential
role of theVHLpathway in cardiopulmonary physiology. It has
demonstrated profound abnormalities in ventilatory and
pulmonary vascular control in affected individuals.
Methods
Participants
Physical characteristics of the participants are given in
Table 1. Patients with CP were identiﬁed from a previous
study [9] and recruited through their respective consultant
haematologists. Each patient was homozygous for the classic
Chuvash mutation and had been treated with long-term
venesection to maintain a normal haemoglobin and haema-
tocrit. No patient had been venesected within several weeks
of the experiment. They had no other medical disorders, had
no history of complications, and were asymptomatic except
for occasional headaches. The size of the CP patient group
was limited by the rarity of the condition in the United
Kingdom. The normal control group comprised six age- and
sex-matched healthy volunteers who were recruited by
advertisement. The CP patient group (age 22.3 6 5 y, mean
6 SD) and the normal control group (24.2 6 5 y) did not
differ signiﬁcantly in age, height, weight, or body mass index.
A further three patients were recruited as sex-matched
polycythaemia control participants: two men diagnosed with
acquired idiopathic erythrocytosis and one woman with
polycythaemia vera. No mutations were detected on sequenc-
ing the VHL gene in these patients. Each was otherwise in
good health and had been chronically venesected to a normal
hematocrit. These patients were somewhat older than the CP
patient group (Table 1) but were otherwise similar. The
female polycythaemia control participant was taking daily
aspirin and citalopram, and one male polycythaemia control
was taking daily atenolol, aspirin, and simvastatin for
cardiovascular disease prophylaxis. Otherwise, participants
were taking no medications, vitamin supplements, or caf-
feine. The study had been approved by the Oxfordshire
Clinical Research Ethics Committee, and each participant
provided written informed consent.
Studies of HIF-Regulated Gene Expression
These studies were undertaken to conﬁrm differences in
HIF-regulated gene expression at the mRNA level in CP
patients compared with normal controls. Mononuclear cells
were isolated by centrifugation of venous blood over a
density gradient medium (Ficoll-Paque Plus, Amersham
Biosciences, Chalfont, United Kingdom). The mononuclear
cells were resuspended in 40 ml of RPMI 1640 cell culture
medium supplemented with 10% fetal bovine serum, L-
glutamine, and penicillin/streptomycin antibiotics (Sigma-
Aldrich, Gillingham, United Kingdom). The cells were placed
in tissue culture dishes with a hydrophilic base (Vivascience,
Table 1. Participant Characteristics
Participant Type Age (y) Sex Height (m) Weight (kg)
CP patient 17 Male 1.77 58
CP patient 27 Female 1.68 70
CP patient 23 Male 1.76 50
Normal control 18 Male 1.79 75
Normal control 20 Male 1.8 75
Normal control 28 Female 1.68 68
Normal control 30 Female 1.55 54
Normal control 25 Male 1.82 85
Normal control 24 Male 1.76 82
Polycythaemia control 33 Male 1.75 75
Polycythaemia control 53 Female 1.75 66
Polycythaemia control 40 Male 1.75 75
DOI: 10.1371/journal.pmed.0030290.t001
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Hannover, Germany) at 37 8C for 30 min to allow for
adherence of the monocytes to the base. The supernatant
containing the lymphocytes was then removed and aliquotted
into eight tissue culture dishes in which the base was both
hydrophobic and gas permeable (Vivascience). Lymphocytes
were incubated for 20 h at 37 8C in 5% carbon dioxide and at
one of eight different oxygen tensions (20%, 10%, 5%, 2%,
1%, 0.5%, 0.2%, or 0.1%). The cells were then harvested and
RNA was isolated using a column-based centrifugation
extraction protocol (RNAqueous-4PCR; Ambion-Europe,
Huntingdon, United Kingdom). RNA samples were reverse
transcribed using random hexamer primers, and the HIF-
regulated genes Aldolase C and vascular endothelial growth factor
(VEGF) were quantiﬁed by real-time quantitative PCR using
Taqman primers and probes (Applied Biosystems, Warring-
ton, United Kingdom). The gene b2-microglobulin was used as
an internal experimental control and was quantiﬁed by the
same method. A standard calibrator sample of cDNA was
assayed for these three genes with each set of real-time
quantitative PCR reactions. This sample was derived from the
pooled RNA of two 20-h incubations of lymphocytes at 20%
and 0.1% oxygen. Levels of gene expression relative to the
calibrator sample were corrected for differences in the PCR
efﬁciencies of the primers and probes used for each gene [10].
This entire procedure was repeated for blood samples drawn
on three separate days from each of three CP patients and
three age- and sex-matched normal controls.
Physiology Protocols
For each participant, the experimental observations were
made during the course of a single day. Participants reported
to the laboratory at 8:30 A.M., where their air-breathing end-
tidal partial pressure of oxygen (PETO2) and carbon dioxide
(PETCO2) were measured, and venous and arterial blood
samples were drawn. Each participant then undertook an
identical series of four separate protocols, with 20 min
separating each protocol. The ﬁrst two protocols determined
the participants’ responses to very mild hypoxia, which
approximated the level of hypoxia commonly experienced
during commercial air travel. An initial 5 min of euoxia
(PETO2 of 100 mm Hg) was followed by 10 min of hypoxia at
PETO2 of 70 mm Hg, which was then followed by a ﬁnal 5 min
of euoxia. The second two protocols followed an identical
time course but determined responses to moderate hypoxia,
using a stimulus PETO2 of 50 mm Hg rather than 70 mm Hg.
This was close to the level of hypoxia experienced during
acute exposure to an altitude of 3,500 m. Isocapnia was
maintained throughout all four protocols, with PETCO2
maintained close to each participant’s baseline value.
Experimental Technique
Gas control during the four protocols was achieved using a
technique known as dynamic end-tidal forcing, whereby a
computer-controlled fast gas-mixing system allows the alveo-
lar partial pressure of oxygen (PO2) to be manipulated rapidly
and accurately while at the same time maintaining alveolar
partial pressure of carbon dioxide (PCO2) constant [11]. Each
protocol was conducted with the participant reclining in the
left lateral position and breathing through a mouthpiece
whilst wearing an occlusive nose clip. Ventilation was
measured using a turbine volume-measuring device [12], and
these data were averaged from the two protocols undertaken
at each level of hypoxia. Respired gases were analysed
continuously by mass spectrometry. These data were logged
in real time to a personal computer that was at the same time
controlling the end-tidal gas composition. A Hewlett-Packard
(Palo Alto, California, United States) Sonos 5500 ultrasound
machine with an S4 two-dimensional transducer (2–4 MHz)
was used to perform continuous echocardiography. During
the ﬁrst protocol at each level of hypoxia, pulmonary vascular
tone was assessed using a standard Doppler technique that has
been extensively validated [13–20]. In this technique, the
maximum velocity of a regurgitant jet of blood through the
tricuspid valve is measured during systole. The maximum
systolic pressure gradient across the tricuspid valve (DPmax) is
then calculated beat by beat from this velocity using
Bernoulli’s equation. Right atrial pressure is unaffected by
hypoxia [21], so changes in DPmax reﬂect changes in systolic
pulmonary artery pressure. During the second protocol at
each level of hypoxia, cardiac output was determined beat by
beat using Doppler echocardiography to measure the velocity
of systolic blood ﬂow through the aortic valve [14,15]. Heart
rate was monitored by electrocardiography, and blood
pressure was measured each minute using an automated cuff.
Breath-by-breath measurements of pulmonary ventilation
and beat-by-beat measurements of DPmax, cardiac output,
and heart rate were averaged over 1-min periods.
Statistical Analyses
Speciﬁc differences between CP patients and normal
controls were assessed statistically using Student’s unpaired
t-test (Microsoft Excel; Microsoft, Seattle, Washington, United
States) and were considered signiﬁcant at the p , 0.05 level.
Other general comparisons of the effects of hypoxia were
performed using a univariate repeated measures ANOVA,
using the Greenhouse–Geisser correction to derive the
degrees of freedom (SPSS statistical package; SPSS, Chicago,
Illinois, United States).
Results
The main results are presented as a comparison between
the CP patient group and the age- and sex-matched normal
healthy controls. The ﬁnal section presents results from the
polycythaemia control participants, as a comparison both
with the normal controls and with the CP patients.
Baseline Measurements
Results obtained from venous and arterial blood analyses
are shown in Table 2. The arterial PCO2 was on average 6 mm
Hg lower in the CP patients than in the matched normal
controls (p , 0.05). All CP patients had been chronically
treated with venesection, and had normal haemoglobin and
haematocrit with concomitant iron deﬁciency.
Studies of Gene Expression
Basal (non-hypoxic) expression of the HIF-regulated genes
studied was signiﬁcantly higher in the CP patient group (p ,
0.05; Figure 1). Aldolase C expression was 130% greater than in
the controls, while VEGF expression was 90% greater. Both
genes were induced by hypoxia, but at the most marked level
of hypoxia, expression was no longer signiﬁcantly greater in
the CP patients. At this level of hypoxia, Aldolase C expression
was only 34% greater than in the controls, and VEGF
expression was only 37% greater. Thus, the effect of the
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VHL mutation was most striking under euoxic conditions,
when the rate of hydroxylation of HIF-a is at its fastest.
Pulmonary Ventilatory Measurements
Figure 2 illustrates pulmonary ventilation at baseline and
in response to hypoxia. During euoxia, ventilation was
sometimes greater in the CP patient group than in the
normal control group. Exposure to mild hypoxia provoked a
2.8-fold greater increase in ventilation in CP patients than in
normal controls (p , 0.02), in whom there was very little
change in ventilation. For normal control participants,
although ventilation increased more with moderate than
mild hypoxia, all protocols were well tolerated. In contrast,
the CP patients tolerated moderate hypoxia poorly, and one
patient withdrew from the moderate hypoxia protocol with
nausea and severe dyspnea. The rise in ventilation produced
by moderate hypoxia was 2.4-fold greater in the CP patient
group (p , 0.05).
Pulmonary Vascular Measurements
The CP patients displayed an abnormally high set point
around which pulmonary arterial pressure was regulated,
which was almost double that of the control group (p , 0.005;
Figure 2) and which, assuming a standard right atrial pressure
of 5 mm Hg, exceeded the cut-off for pulmonary hyper-
tension (pulmonary arterial pressure greater than 25 mm Hg)
[22]. In normal control participants, as expected, exposure to
mild hypoxia produced only a very small rise in DPmax,
reﬂecting their minimal pulmonary vasoconstrictive re-
sponse. However, the increase in DPmax provoked by the
same stimulus was 10.7-fold greater in the CP patient group (p
, 0.01). Their DPmax response to moderate hypoxia was
likewise extremely abnormal, and was 5.8-fold greater than
that for the normal control group (p , 0.001).
Systemic Vascular Measurements
There was a trend towards a higher baseline heart rate in
CP patients than normal control participants (p¼0.06; Figure
3), and upon transition to mild hypoxia, heart rate increased
3.2-fold more in the CP patient group (p , 0.005); the
corresponding difference was not statistically signiﬁcant with
moderate hypoxia (1.6-fold, p ¼ 0.21). Changes in cardiac
output followed a similar pattern to changes in heart rate but
did not differ signiﬁcantly between the two groups.
Polycythaemia Control Participants
The polycythaemia control participants, like the CP
patients, were iron-deﬁcient with microcytic indices but
normal haemoglobin and haematocrit (Table 2). However, the
polycythaemia control group, unlike the CP patient group,
had a normal arterial PCO2 (signiﬁcantly higher than that of
the CP patient group, p , 0.01). Baseline pulmonary and
systemic blood pressures were higher in the polycythaemia
controls compared with the normal control group, but it
should be noted that the polycythaemia control participants
were older. The data from the polycythaemia control
participant taking atenolol were excluded from the analyses
of systemic vascular data.
The mean responses (ventilation, DPmax, heart rate, blood
pressure, and cardiac output) of the polycythaemia control
Table 2. Arterial and Venous Blood Analyses
Analysis (Normal Range)a CP Patients
(n ¼ 3)
Normal Control
Participants (n ¼ 6)
p-Value Polycythaemia Control
Participants (n ¼ 3)
p-Value
Arterial PO2 (83–108 mm Hg) 102.1 6 2.5 98.9 6 10.9 0.65 — —
Arterial PCO2 (35–45 mm Hg) 34.2 6 1.8 40.3 6 4.1 ,0.05 41.5 6 1.7 ,0.01
Arterial pH (7.35–7.45) 7.41 6 0.02 7.38 6 0.02 ,0.05 7.38 6 0.02 0.18
Haemoglobin (12–17 g/dl) 14.1 6 2.1 13.7 6 1.7 0.76 13.9 6 2.0 0.93
Haematocrit (0.36–0.50 l/l) 0.48 6 0.08 0.42 6 0.05 0.26 0.45 6 0.03 0.69
Mean corpuscular volume (83–101 fl) 64.0 6 5.7 88.8 6 3.1 ,0.001 78.5 6 10.6 0.11
Iron (11–31 lmol/l) 3.5 6 0.8 17.0 6 3.7 ,0.001 12.4 6 14.3 0.34
Ferritin (10–300 lg/l) 2.2 6 1.3 48.5 6 37.4 0.08 8.4 6 4.3 0.07
Transferrin (1.8–3.6 g/l) 3.8 6 0.3 2.6 6 0.5 ,0.02 3.3 6 0.2 0.08
Values are mean 6 standard deviation. p-Values compare the CP patient group with each respective control group.
aWhere normal ranges vary with sex, the widest range is shown.
DOI: 10.1371/journal.pmed.0030290.t002
Figure 1. Aldolase C and VEGF mRNA Expression at Different Oxygen
Tensions
Lymphocytes were isolated from venous blood taken from CP patients
and normal control participants, and incubated at eight different levels
of oxygen tension prior to RNA isolation. Gene expression is shown
relative to a standard calibrator sample. Basal gene expression at 20%
oxygen was significantly higher in CP patients for both Aldolase C (A) and
VEGF (B) (p , 0.05). Both genes were induced by hypoxia, and at the
lowest oxygen tension (0.1%) expression was no longer significantly
different for either gene. Values are mean 6 standard error of the mean.
Asterisks indicate p , 0.05 (unpaired t-test).
DOI: 10.1371/journal.pmed.0030290.g001
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group to hypoxia are shown in Figures 2 and 3. In addition,
Figure 4 illustrates the sensitivities to hypoxia of the
individual participants from all three experimental groups.
These are expressed in terms of the number of (normal
control group) standard deviations that each participant’s
response deviated from the mean response of the normal
healthy control participants. The responses of the polycy-
thaemia control group never differed signiﬁcantly from those
of the normal control group (repeated measures ANOVA).
This demonstrates that the major alterations in physiology
present in the CP patients were not present in the
polycythaemia control participants. As a ﬁnal check on the
overall results, the CP patient group was compared with the
pooled control groups using repeated measures ANOVA. In
all cases this analysis conﬁrmed the signiﬁcant ﬁndings
reported in the preceding sections.
Discussion
In CP the VHL–HIF signalling pathway is speciﬁcally and
systemically impaired, uniquely facilitating human research
into this transcriptional system. Previous phenotyping studies
using transformed lymphocyte cell lines demonstrated in-
creased basal expression of HIF-a with up-regulation of
downstream target genes such as EPO and VEGF [8]. Using
fresh lymphocytes, we have now conﬁrmed that expression of
classic HIF-regulated genes (of disparate functions) is in-
Figure 3. Systemic Vascular Responses to Mild and Moderate Hypoxia
(A and B) Heart rate. Mild hypoxia provoked a rise of 11.7 beats/min in
the CP patient group, compared with 3.6 beats/min in normal control
participants (p , 0.05). No other statistically significant differences in
systemic vascular responses were detected between these two groups.
(C and D) Blood pressure, showing systolic pressure (upper plot) and
diastolic pressure (lower plot).
(E and F) Cardiac output, assessed non-invasively using Doppler
echocardiography.
All responses are shown during mild (A, C, and E) and moderate (B, D,
and F) hypoxia. Values are mean 6 standard error of the mean.
DOI: 10.1371/journal.pmed.0030290.g003
Figure 2. End-Tidal Gas Control, Ventilatory, and Pulmonary Vascular
Responses to Mild and Moderate Hypoxia
(A and B) End-tidal gas control. PETO2 and PETCO2 were well controlled.
PETO2 was well matched between all groups. PETCO2 was lower in the CP
patient group, reflecting this group’s lower baseline air-breathing PETCO2.
(C and D) Ventilation, given at body temperature and pressure, saturated
with water vapour. Mild hypoxia provoked an increase in ventilation of
4.4 l/min in the CP patients versus 1.6 l/min in normal controls (p, 0.05),
while moderate hypoxia induced increases of 24.5 versus 10.0 l/min in
these two groups, respectively (p , 0.05).
(E and F) Pulmonary vascular tone. This was assessed using Doppler
echocardiography to determine DPmax, a standard non-invasive index of
pulmonary vascular tone. With mild hypoxia, DPmax increased by 11.5
mm Hg in the CP patient group compared with only 1.1 mm Hg in the
normal control group (p , 0.05). Moderate hypoxia stimulated a rise in
DPmax of 35.3 mm Hg compared with 6.1 mm Hg in these two groups,
respectively (p , 0.001).
All responses are shown during mild (A, C, and E) and moderate (B, D,
and F) hypoxia. Values are mean 6 standard error of the mean.
DOI: 10.1371/journal.pmed.0030290.g002
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creased under non-hypoxic conditions in CP patients. We
have also shown that differences in gene expression are less
distinct in hypoxia, consistent with a relative diminution in
the impact of the mutant VHL when oxygen tension falls and
the rate of hydroxylation of HIF-a slows. A retrospective
matched cohort study conducted in Chuvashia found that
homozygosity for the Chuvash VHL mutation was associated
with vertebral haemangiomas, varicose veins, lower systemic
blood pressures, and premature mortality partially related to
cerebrovascular and thrombotic events [23]. The current study
focuses on the phenotypic consequences of this mutation in
systemic respiratory and cardiovascular physiology.
The lower air-breathing PCO2 measured in the CP patient
group indicates an altered set point for respiratory control in
the direction of an elevation in pulmonary ventilation (i.e.,
ventilation is somewhat higher than normal in relation to
metabolism). This is consistent with measurements of their
ventilation during isocapnic euoxia, which tended to be
higher than for the controls although the difference was not
statistically signiﬁcant. It is striking that CP patients had both
a reduced PCO2 set point for the respiratory controller and an
abnormally high acute hypoxic ventilatory sensitivity, as
together these are characteristic of individuals who are
acclimatised to hypoxia at high altitude [24,25]. Indeed, the
difference in ventilatory sensitivity to hypoxia between CP
patients and controls was likely to be even greater than
reported, since the relative hypocapnia of the patients would
have inhibited their ventilatory response [26]. These results
are clearly consistent with the notion that the VHL–HIF
system is involved in human ventilatory acclimatisation to
hypoxia, and establish an important role for VHL in
regulating respiratory control in hypoxia-naı¨ve individuals.
CP patients were found to have a degree of pulmonary
arterial hypertension. This most probably reﬂects HIF-
regulated elevation in pulmonary vasomotor tone, although
the increased rate of thrombotic events reported in CP [23]
raises the theoretical possibility of chronic thromboembolic
pulmonary hypertension as an alternative underlying mech-
anism. However, chronic thromboembolic pulmonary hyper-
tension is rare even in patients with chronic uncontrolled
myeloproliferative disease [27]. It is very unlikely to be
present in young venesected individuals such as the patients
in our study, who have no antecedent thrombotic history,
hypoxaemia, or other clinical manifestations of thromboem-
bolic disease. Furthermore, it should be noted that the
presence of pulmonary hypertension in our patient group
does not explain their very high pulmonary vascular
sensitivity to hypoxia. A previous study measured pulmonary
vasoresponsiveness to hypoxia in 26 eucapnic patients with
pulmonary hypertension related to chronic obstructive lung
disease [28]. For equivalent decrements in arterial PO2, the
increase in pulmonary arterial pressures produced by
hypoxia was 4–7 times smaller in the patients with chronic
lung disease than in our CP patient group. Other studies
using animals have also shown that hypoxic pulmonary
vasoconstriction is blunted by increased pulmonary arterial
pressures [29].
It is therefore remarkable that the CP patient group
displayed such exquisite hypoxic pulmonary vascular sensi-
tivity. Mild hypoxia provoked peak values for DPmax that
correspond to systolic pulmonary arterial pressures of
approximately 45 mm Hg, while the moderate hypoxic
stimulus provoked extraordinary peak systolic pulmonary
arterial pressures of approximately 70 mm Hg. If hypoxia
were to be sustained, pulmonary arterial pressure might rise
considerably higher, because in normal participants a second,
gradual component of hypoxic pulmonary vasoconstriction
develops [14] and continues to intensify for at least another
1–2 h [30]. Prolonged exposure to high pulmonary arterial
pressures leads to right ventricular strain and eventual
failure, introducing the possibility that pulmonary hyper-
tension and exaggerated hypoxic sensitivity contribute to the
premature mortality associated with CP [23]. This ﬁnding also
raises the question of whether affected patients should avoid
high altitudes and minimise long-haul air travel.
Lowered systemic blood pressure has previously been
reported in CP [23], suggesting VHL–HIF may be involved
in setting basal systemic vascular tone. Although no statisti-
cally signiﬁcant differences in blood pressure were seen in
our limited patient sample, our ﬁndings do implicate VHL–
HIF in modulating the heart rate response to acute hypoxia.
In this study, it was clear that each individual with CP was
physiologically very abnormal. There is no evidence to
suggest that these pronounced physiological abnormalities
were confounded by polycythaemia per se. Although relevant
human data are lacking, animal studies have shown that the
Figure 4. Sensitivities to Hypoxia for Individual Participants
Results are shown in terms of the number of (normal control group)
standard deviations by which each participant’s response differed from
the mean response of the normal control participants. The patients with
CP were significantly different from the normal control group in their
ventilatory and pulmonary vascular responses to both mild and
moderate hypoxia, and in their heart rate responses to mild hypoxia.
BP, blood pressure.
DOI: 10.1371/journal.pmed.0030290.g004
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pulmonary vascular response to acute hypoxia is independent
of haematocrit [31], and that the hypoxic ventilatory response
is either inhibited [32] or unchanged [33] acutely by
polycythaemia. In any case, none of the participants was
polycythaemic at the time of the study, as therapeutic
venesection had normalised the haemoglobin and the
haematocrit in the affected patients.
Treatment of polycythaemia with venesection renders
patients iron-deﬁcient. Iron is an obligate co-factor in the
prolyl hydroxylation reaction by which HIF is regulated [4,5],
and iron deﬁciency inhibits this reaction, at least in vitro.
Thus, it is possible that, through effects on HIF-regulated
gene expression, iron deﬁciency contributed to the physio-
logical abnormalities seen in the CP patients. Our study did
not detect any signiﬁcant physiological differences between
the polycythaemia control group, who were clearly iron-
deﬁcient, and the normal controls. This tends to suggest that
associated iron deﬁciency is not a factor underlying the
abnormalities observed within the CP patient group. It
should nevertheless be noted that the polycythaemia control
participants were not as severely iron-deﬁcient as the CP
patients, and also that there was some suggestion that the
ventilatory response to moderate (but not mild) hypoxia of
the polycythaemia control group was intermediate between
that of the normal control and CP groups. Thus, while we
were unable to show that the iron deﬁciency present in
polycythaemia control participants resulted in abnormal
cardiopulmonary physiology, the number of participants
studied was small and the possibility clearly remains that
iron deﬁciency may phenocopy VHL loss of function to some
limited extent.
One of the polycythaemia control participants was taking
atenolol. Results from this participant were excluded from
the analysis of systemic vascular data but were included in all
other analyses. Ventilatory responses to acute hypoxia are not
affected by b-adrenergic receptor blockade [34,35], and
animal studies suggest that b-receptor antagonists either
have no effect on hypoxic pulmonary vasoconstriction [36] or
enhance the phenomenon somewhat [37].
Overall, the results from the polycythaemia control
participants support the notion that the cardiopulmonary
abnormalities in CP result directly from dysregulation of the
VHL pathway rather than indirectly from the haematological
manifestations of the disease.
The major known role of VHL is its regulation of the HIF
transcriptional system [2]. The results from the present study
and others [8] demonstrate that the Chuvash VHL mutation
results in up-regulation of at least some HIF-responsive genes
under conditions of euoxia. Furthermore, a role for the HIF
system in cardiopulmonary regulation has been observed
through the attenuation of cardiopulmonary responses to
hypoxia in mice that are heterozygously deﬁcient for func-
tional HIF genes [38–41]. This down-regulation of cardiopul-
monary responses in HIF-aþ/mice is consistent with the up-
regulation of cardiopulmonary responses seen in the CP
patients in this study. It thus seems likely that the phenotype
observed in the current study results from effects of VHL on
the HIF system, though the involvement of other (as yet
unknown) proteins with which VHL may interact cannot be
excluded.
Involvement of VHL–HIF in vasomotor regulation is
consistent with the nature of some of the genes HIF is known
to regulate in humans and animals. These genes include
endothelin-1, endothelial nitric-oxide synthase, tyrosine hydroxylase,
a1b-adrenergic receptor, adrenomedullin, heme oxygenase-1, and atrial
natriuretic peptide [42]. Tyrosine hydroxylase has also been
hypothetically linked to ventilatory control through its
regulation of catecholamine biosynthesis in the carotid body
[43]. In addition, transgenic mice over-expressing EPO in the
brain were recently shown to have abnormal ventilatory
responses to hypoxia [44], raising the further possibility that
the VHL–HIF pathway inﬂuences ventilation through regu-
lating cerebral expression of EPO.
Although the number of patients in our study was small,
and as such our ﬁndings may not be completely representa-
tive of CP patients overall, our ﬁndings nevertheless
demonstrate that a relatively subtle disorder of HIF degra-
dation profoundly alters human cardiopulmonary physiology.
Patients with CP had elevated basal ventilation and pulmo-
nary vascular tone, with extremely high ventilatory, pulmo-
nary vasoconstrictive, and heart rate responses to acute
hypoxia. The abnormalities they displayed mimicked those
caused by acclimatisation to hypoxia at high altitude. We
conclude that, in humans, the VHL–HIF transcriptional
signalling pathway, which is central to intracellular oxygen
sensing, also appears to play a major role in calibrating the
organ systems upon which cellular oxygen delivery ultimately
depends. Further research is required to investigate the exact
mechanisms involved. Our study also has implications for
current HIF-related therapeutic research, much of which is
directed towards pharmacological inhibition of the prolyl
hydroxylases that negatively regulate HIF. Such therapies are
intended to up-regulate HIF-dependent genes and promote
angiogenesis in ischaemic/hypoxic vascular disease, but will
now require surveillance for the undesired physiological
effects of exaggerated hypoxic responses and elevated
pulmonary vascular tone. Conversely, HIF inhibitors under
investigation as anti-cancer treatments may have opposite
physiological effects, conceivably introducing potential ap-
plications for these agents in diseases such as pulmonary
hypertension.
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Editors’ Summary
Background. Human cells (like those of other multicellular animals) use
oxygen to provide the energy needed for daily life. Having not enough
oxygen is a problem, but having too much is also dangerous because it
damages proteins, DNA, and other large molecules that keep cells
functioning. Consequently, the physiological systems—including the
heart, lungs, and circulation—work together to balance oxygen supply
and demand throughout the body. When oxygen is limiting (a condition
called hypoxia), as happens at high altitudes, the cellular oxygen supply
is maintained by increasing the heart rate, increasing the speed and
depth of breathing (hyperventilation), constricting the blood vessels in
the lung (pulmonary vasoconstriction), and increasing the number of
oxygen-carrying cells in the blood. All these physiological changes
increase the amount of oxygen that can be absorbed from the air, but
how they are regulated is poorly understood. By contrast, researchers
know quite a bit about how individual cells respond to hypoxia. When
oxygen is limited, a protein called hypoxia-inducible factor (or HIF)
activates a number of target proteins that help the cell get enough
oxygen (for example, proteins that stimulate the growth of new blood
vessels). When there is plenty of oxygen, another protein, called von
Hippel–Lindau tumor suppressor (abbreviated VHL), rapidly destroys HIF.
Recently, researchers discovered that a genetic condition called Chuvash
polycythaemia, characterised by the overproduction of red blood cells, is
caused by a specific defect in VHL that reduces its ability to destroy HIF.
As a result, the expression of certain HIF target proteins is increased even
when oxygen levels are normal.
Why Was This Study Done? Chuvash polycythaemia is very rare, and so
far little is known about how this genetic abnormality affects the
physiology and long-term health of patients. By studying heart and lung
function in patients with Chuvash polycythaemia, the researchers
involved in this study hoped to discover more about the health
consequences of the condition and to find out whether the VHL–HIF
system controls systemic responses to hypoxia as well as cellular
responses.
What Did the Researchers Do and Find? The researchers recruited and
studied three patients with Chuvash polycythaemia, and, as controls for
the comparison, several normal individuals and patients with an
unrelated form of polycythaemia. They then measured how the lungs
and hearts of these people reacted to mild hypoxia (similar to that
experienced on commercial air flights) and moderate hypoxia (equiv-
alent to being on the top of an Alpine peak). They found that patients
with Chuvash polycythaemia naturally breathe slightly quicker and
deeper than normal individuals, and that their breathing rate increased
dramatically and abnormally when oxygen was reduced. They also found
that at normal oxygen levels the pulmonary blood vessels of these
patients were more constricted than those of control individuals, and
that they reacted more extremely to hypoxia. Similarly, the normal heart
rate of the patients was slightly higher than that of the controls and
increased much more in response to mild hypoxia.
What Do These Findings Mean? The physiological differences
measured by the researchers between Chuvash polycythaemia patients
and control individuals are similar to the adaptations seen in people
traveling to high altitudes where oxygen is limited. Thus, the VHL–HIF
proteins may regulate the response to different oxygen concentrations
both in individual cells and at the systemic level, although more
physiological studies are needed to confirm this. Because the pulmonary
blood vessels of patients with Chuvash polycythaemia are always
abnormally constricted, and even more so when oxygen is limited, these
people should avoid living at high altitude and should minimise air
travel, suggest the researchers. The increased blood pressure in their
lungs (pulmonary hypertension) could conceivably cause heart failure
under such circumstances. Finally, this study has implications for the
development of drugs directed at the VHL–HIF system. Agents are
currently being designed to promote the development of new blood
vessels after strokes or heart attacks by preventing the destruction of
HIF, but based on the findings here such agents might have undesirable
physiological affects. Conversely, HIF inhibitors (which act as anti-cancer
reagents by increasing hypoxia in the centre of tumors and so inhibiting
their growth) might be useful in the treatment of pulmonary hyper-
tension.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030290.
 Online Mendelian Inheritance in Man page on Chuvash polycythaemia
 Information from the VHL Family Alliance on von Hippel–Lindau
disease, including information on Chuvash polycythaemia
 Wikipedia page on polycythaemia and von Hippel–Lindau disease
(note: Wikipedia is a free online encyclopaedia that anyone can edit)
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